Blog
RSS FeedPosted by Michael Wonder on 26 Jul 2023
Afamelanotide acetate for the treatment of patients with erythropoietic protoporphyria
27 July 2023 - NICE has published final evidence-based recommendations on the use of afamelanotide acetate (Scenesse) for the treatment ...
Posted by Michael Wonder on 26 Jul 2023
Selpercatinib for untreated RET fusion positive advanced non-small-cell lung cancer
26 July 2023 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for adults with advanced, ...
Posted by Michael Wonder on 20 Jul 2023
New Government consultation on medicine clawbacks will harm investment, says ABPI
19 July 2023 - In a move that will further damage UK life sciences investment, the Government has launched a ...
Posted by Michael Wonder on 13 Jul 2023
Semaglutide for the treatment of overweight and obese adolescents
13 July 2023 - NICE is unable to make a recommendation on the use of semaglutide (Wegovy) on the NHS for ...
Posted by Michael Wonder on 13 Jul 2023
Dr. Reddy’s proposed rituximab biosimilar application accepted for review by US FDA, EMA and MHRA
12 July 2023 - Following dossier submission in April 2023, the regulatory agencies have now accepted the dossier for review. ...
Posted by Michael Wonder on 12 Jul 2023
Lorlatinib for the treatment of adults with advanced ALK positive non-small-cell lung cancer
12 July 2023 - NICE has published final evidence-based recommendations on the use of lorlatinib (Lorviqua) for the treatment of ...
Posted by Michael Wonder on 11 Jul 2023
MHRA authorises GSK’s Arexvy, the first respiratory syncytial virus vaccine for older adults
10 July 2023 - The authorisation is based on phase III efficacy data in older adults. ...
Posted by Michael Wonder on 06 Jul 2023
MHRA grants marketing authorisation for Opzelura (ruxolitinib) cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents
5 July 2023 - Phase 3 data supporting the approval show treatment with ruxolitinib cream resulted in improved facial and ...
Posted by Michael Wonder on 05 Jul 2023
MHRA puts supporting patient access to innovation at the heart of its new Corporate Plan 2023-26
4 July 2023 - A new, visionary Corporate Plan, setting out how the Medicines and Healthcare products Regulatory Agency plans to ...
Posted by Michael Wonder on 05 Jul 2023
Rimegepant sulphate for the prevention of migraine
5 July 2023 - NICE has published final evidence-based recommendations on the use of rimegepant sulphate (Vydura) for the prevention ...
Posted by Michael Wonder on 05 Jul 2023
Olaparib for the maintenance treatment of adults with relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after two or more courses of platinum-based chemotherapy
5 July 2023 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the maintenance treatment ...
Posted by Michael Wonder on 29 Jun 2023
Secukinumab for the treatment of patients with moderate to severe hidradenitis suppurativa
29 June 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jun 2023
Deucravacitinib for the treatment of patients with moderate to severe plaque psoriasis
28 June 2023 - NICE has published final evidence-based recommendations on the use of deucravacitinib for the treatment of adults ...
Posted by Michael Wonder on 27 Jun 2023
NICE launches public consultation on updates to health technology evaluations manual
27 June 2023 - A public consultation on updates to NICE’s health technology evaluations manual is now open. ...
Posted by Michael Wonder on 27 Jun 2023
More evidence needed to recommend type 2 diabetes treatment tirzepatide
27 June 2023 - More evidence is needed on the clinical and cost effectiveness of a new treatment option for patients ...